Post on 22-Jan-2018
What’s in the Pipeline for Diabetes Care?
Lenley Adams, MD FRCPC FACP Diabetes Ma>ers May 12, 2017
Presenter Disclosure
• Presenter: Lenley Adams, MD FRCPC FACP
• Rela,onships with commercial interests: – Advisory Board: NovoNordisk, Sanofi, Medtronic, Merck – Speakers Honoraria: AstraZeneca, NovoNordisk, Sanofi, Medtronic,
Merck, Boehringer Ingelheim/Lilly, Janssen, Valeant
ObjecGve
• Review upcoming diabetes treatment and technologies
Evidence
• Ongoing CV outcome trials
Insulin
• longer acGng insulins – Insulin degludec-‐ fall 2017
• faster acGng rapid analogs – Faster acGng insulin aspart-‐ Fiasp-‐ available
• SEB/ biosimilars
Insulin
• oral insulins
• glucose dependent insulins
GLP1 Receptor Agonists
• Currently injectable once daily or weekly • Oral GLP1-‐ RA • GLP-‐1/GIP dual-‐agonist
CombinaGon therapy
• Long acGng insulin with GLP1 receptor agonist – Insulin degludec and LiragluGde – Insulin glargine and LixisenaGde
Type 2 Diabetes Remission
• Early insulin for inducGon of remission
Monitoring
• CGM/ Libre
Insulin Pumps
• Patch pumps • Hybrid pumps
ArGficial Pancreas • Dual hormone pumps with sensor-‐ bionic pancreas
Glucagon
• Glucagon-‐ intranasal, analogs
The near future • Stem cell derived islet cell replacement
• Diabetes Canada 2018 Guidelines
What’s coming?